$BLGO BioLargo Reports Q3 2025 Operating and Finan
Post# of 39842
(Total Views: 56)
Posted On: 11/17/2025 8:51:29 AM
$BLGO BioLargo Reports Q3 2025 Operating and Financial Results
https://www.accessnewswire.com/newsroom/en/ch...ts-1102916
$4.5 Million Cash Balance at Quarter-End as High-Impact Technology Portfolio Advances
WESTMINSTER, CALIFORNIA / ACCESS Newswire / November 17, 2025 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve challenging environmental and cleantech problems, today announced financial and operational results for the three and nine months ended September 30, 2025. The Company also held its quarterly earnings call on November 14, and a full replay-including the investor presentation-is available on the BioLargo investor relations website.
Dennis P. Calvert, President and CEO of BioLargo, commented: "We continue to make meaningful progress across our portfolio as we advance both technical developments and commercialization efforts. Our technologies have been validated in multiple markets, and our team remains focused on building the right partnerships to unlock long-term growth. Financially, the Company remains healthy with a $4.5 million cash balance, no toxic debt, and a growing pipeline of opportunities across several industries."
"As previously disclosed, we filed a nine-count federal lawsuit against Pooph Inc. related to the Pooph agreements. This action is an important step to protect our intellectual property and to enable us to redeploy our proven technology with partners that share our values around quality, transparency, and integrity. We do not expect the lawsuit to materially impact any other business units or growth initiatives."
"We are optimistic about the next phase of our commercialization efforts. Our wound care and surgical product lines are approaching launch. Our PFAS treatment technology has made significant technical strides and its commercial demonstration site is preparing to go live. Meanwhile, our Cellinity™ battery platform continues to show promise as a potential breakthrough in grid-scale energy storage, and we are actively working with prospective factory partners to secure the capital required to move into commercialization."
Q3 2025 Financial Highlights
Revenues:
Q3 revenues were $1,210,000.
Year-to-date revenues were $7,255,000.
The year-over-year decline was primarily attributable to reduced sales of the Pooph-branded pet odor product following license revocation due to non-payment and unauthorized activities by the licensee.
Balance Sheet (as of September 30, 2025):
Stockholders' equity: $3,322,000
Total assets: $9,237,000
Total liabilities: $5,915,000
Cash and cash equivalents: $4,546,000
BioLargo ended the quarter with no toxic debt.
Learn more about BioLargo's environmental technologies at https://www.biolargo.com.
https://www.accessnewswire.com/newsroom/en/ch...ts-1102916
$4.5 Million Cash Balance at Quarter-End as High-Impact Technology Portfolio Advances
WESTMINSTER, CALIFORNIA / ACCESS Newswire / November 17, 2025 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve challenging environmental and cleantech problems, today announced financial and operational results for the three and nine months ended September 30, 2025. The Company also held its quarterly earnings call on November 14, and a full replay-including the investor presentation-is available on the BioLargo investor relations website.
Dennis P. Calvert, President and CEO of BioLargo, commented: "We continue to make meaningful progress across our portfolio as we advance both technical developments and commercialization efforts. Our technologies have been validated in multiple markets, and our team remains focused on building the right partnerships to unlock long-term growth. Financially, the Company remains healthy with a $4.5 million cash balance, no toxic debt, and a growing pipeline of opportunities across several industries."
"As previously disclosed, we filed a nine-count federal lawsuit against Pooph Inc. related to the Pooph agreements. This action is an important step to protect our intellectual property and to enable us to redeploy our proven technology with partners that share our values around quality, transparency, and integrity. We do not expect the lawsuit to materially impact any other business units or growth initiatives."
"We are optimistic about the next phase of our commercialization efforts. Our wound care and surgical product lines are approaching launch. Our PFAS treatment technology has made significant technical strides and its commercial demonstration site is preparing to go live. Meanwhile, our Cellinity™ battery platform continues to show promise as a potential breakthrough in grid-scale energy storage, and we are actively working with prospective factory partners to secure the capital required to move into commercialization."
Q3 2025 Financial Highlights
Revenues:
Q3 revenues were $1,210,000.
Year-to-date revenues were $7,255,000.
The year-over-year decline was primarily attributable to reduced sales of the Pooph-branded pet odor product following license revocation due to non-payment and unauthorized activities by the licensee.
Balance Sheet (as of September 30, 2025):
Stockholders' equity: $3,322,000
Total assets: $9,237,000
Total liabilities: $5,915,000
Cash and cash equivalents: $4,546,000
BioLargo ended the quarter with no toxic debt.
Learn more about BioLargo's environmental technologies at https://www.biolargo.com.
(0)
(0)